What is AsymBio?
AsymBio operates as a high-authority Contract Development and Manufacturing Organization (CDMO) providing end-to-end solutions for the biopharmaceutical industry. By leveraging the deep technical expertise of the Asymchem Group, the company offers a comprehensive suite of services including developability assessment, analytical science, and commercial-scale manufacturing. Their market position is defined by a commitment to accelerating the drug commercialization lifecycle, supporting clients from the initial stages of research through to regulatory approval and large-scale production. The firm is uniquely positioned to address the technical challenges associated with antibodies and complex conjugated drug modalities, ensuring that global pharmaceutical partners can navigate the path to market with increased efficiency and reduced risk.
How much funding has AsymBio raised?
AsymBio has raised a total of $184M across 1 funding round:
Unspecified
$184M
Unspecified (2026): $184M with participation from Asymchem and Hillhouse
Key Investors in AsymBio
Asymchem
Asymchem Inc. is a leading Contract Development and Manufacturing Organization (CDMO) dedicated to serving global pharmaceutical companies with innovative green solutions and advanced drug development services.
Hillhouse
Hillhouse is a full life-cycle private equity firm that manages capital for global institutions, focusing on long-term value creation across the healthcare, business services, and industrial sectors.
What's next for AsymBio?
With this recent strategic investment, AsymBio is poised to accelerate its growth trajectory by scaling its manufacturing capacity and deepening its investment in advanced technology platforms. The company is expected to focus on optimizing its process development workflows to better serve the evolving needs of the biopharmaceutical sector. By strengthening its regulatory affairs and quality control frameworks, AsymBio aims to solidify its reputation as a reliable partner for global innovation. Future initiatives will likely prioritize the integration of sustainable manufacturing practices, aligning with the broader industry shift toward green chemistry and efficient, high-yield production cycles for next-generation therapeutics.
See full AsymBio company page
